BioLineRx (BLRX) Common Equity (2010 - 2025)

BioLineRx's Common Equity history runs 16 years deep, the most recent figure standing at $23.3 million for Q4 2025.

• On a quarterly basis, Common Equity rose 73.43% year-over-year to $23.3 million in Q4 2025; TTM through Dec 2025 was $23.3 million, a 73.43% increase from a year earlier, with the FY2025 full-year figure at $23.3 million, up 73.43% from the prior year.
• Common Equity grew to $23.3 million in Q4 2025 per BLRX's latest filing, from $19.5 million in the prior quarter.
• Across five years, Common Equity topped out at $73.9 million in Q2 2021 and bottomed at $8.5 million in Q3 2024.
• The 5-year median for Common Equity is $22.2 million (2023), against an average of $36.2 million.
• Across the five-year window, Common Equity surged 209.06% in 2021 and plunged 76.35% in 2023, its largest moves.
• Year by year, Common Equity stood at $68.1 million in 2021, then retreated by 25.33% to $50.8 million in 2022, then sank by 73.99% to $13.2 million in 2023, then gained by 1.8% to $13.5 million in 2024, then jumped by 73.43% to $23.3 million in 2025.
• Per Business Quant, the three latest BLRX Common Equity figures stand at $23.3 million (Q4 2025), $19.5 million (Q3 2025), and $20.1 million (Q2 2025).